Reaffirming Buy on Durable AVMAPKI FAKZYNJA Benefit in Recurrent LGSOC, Supported by Robust 2-Year RAMP 201 Data

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Verastem today and set a price target of $18.00.

Andres Y. Maldonado has given his Buy rating due to a combination of factors, foremost among them the strong durability and consistency of clinical benefit seen with the AVMAPKI FAKZYNJA co-pack in recurrent LGSOC. The updated two-year follow-up from the RAMP 201 study shows that key efficacy measures, including duration of response and progression-free survival, remain robust with minimal erosion over time, particularly in KRAS-mutant patients who experience notably prolonged benefit.

Maldonado also underscores that safety remains manageable with low treatment discontinuation, and pharmacokinetic/pharmacodynamic analyses support the approved dosing strategy as optimal for balancing efficacy and tolerability. These findings validate the dual MAPK and FAK inhibition mechanism as a long-term disease control approach and position the regimen as a durable therapeutic backbone in a chronic, MAPK-driven setting, which he believes justifies maintaining a Buy rating and an $18 price target despite remaining questions on breadth of use and long-term competitiveness.

In another report released on April 7, RBC Capital also maintained a Buy rating on the stock with a $15.00 price target.